论文部分内容阅读
Background: Retching, an early component of the emetic reflex, is a common and distressing symptom in children after Nissen fundoplication. Alimemazine (trimeprazine, Vallergan; Castlemead, Herts, UK) is a phenothiazine derivative histamine1 antagonist, which anecdotally relieves the retching symptoms. Material and Methods: A prospective, double-blind, randomized, crossover, placebo-controlled study of 15 neurologically impaired children with retching after Nissen fundoplication over a period of 1 year (December 2002- December 2003). Patients were randomly allocated to receive 1 week each of alimemazine and placebo with crossover. A diary was maintained of retching episodes 1 week before, during, and 1 week after the trial. Dosage of alimemazine used was 0.25 mg/kg 3 times a day (maximum, 2.5 mg per dose). Statistical analysis was done using a paired Student’s t test, where P value of less than .05 was considered significant. Results are presented as mean ± SD. Results: Twelve parents completed the diaries (9 open, 3 laparoscopic Nissen fundoplication). Median age of the child was 36 months (8- 180 months), median duration of retching was 4.5 months (1- 52 months), and mean number of retching episodes per week was 60 ± 29.40. Mean number of retching episodes with alimemazine was 10.42 ± 9.48 vs 47.67 ± 27.79 with a placebo (P < .0001). No adverse effects were reported in those cases that completed the study. Conclusion: At low dose, alimemazine (Vallergan) is a safe and effective drug in the management of retching after Nissen fundoplication.
Background: Retching, an early component of the emetic reflex, is a common and distressing symptom in children after Nissen fundoplication. Alimemazine (trimeprazine, Vallergan; Castlemead, Herts, UK) is a phenothiazine derivative histamine1 antagonist, which anecdotally relieves the retching symptoms. Material and Methods: A prospective, double-blind, randomized, crossover, placebo-controlled study of 15 neurologically impaired children with retching after Nissen fundoplication over a period of 1 year (December 2002-December 2003). Patients were randomly assigned to receive 1 week of of alimemazine and placebo with crossover. A diary was maintained of retching episodes 1 week before, during, and 1 week after the trial. Dosage of alimemazine used was 0.25 mg / kg 3 times a day (maximum, 2.5 mg per dose) . Statistical analysis was done using a paired Student’s t test, where P value of less than .05 was considered significant. Results are presented as mean ± SD. Results: Twelve parents completed the diaries (9 open, 3 laparoscopic Nissen fundoplication). Median age of the child was 36 months (8- 180 months), median duration of retching was 4.5 months (1- 52 months), and mean number of retching episodes per week was 60 ± 29.40. Mean number of retching episodes with alimemazine was 10.42 ± 9.48 vs 47.67 ± 27.79 with a placebo (P <.0001). No adverse effects were reported in those cases that completed the study. Conclusion: At low dose, alimemazine (Vallergan) is a safe and effective drug in the management of retching after Nissen fundoplication.